Accendra Health, Inc.
NYSE:ACH · New York Stock Exchange
+$0.12 today
Vol 0.90M · Avg 0.83M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
238.8%
avg 11.9%
ROIC
8.4%
avg 3.1%
ROA
-44.9%
avg -4.5%
Analysis
ROE is currently the strongest return metric at 238.8% versus its period average of 11.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Edward A. Pesicka | President, Chief Executive Officer & Director | $1.60M | — | 58 | $1.07M | 1.40% |
Jonathan A. Leon | Executive Vice President, Chief Financial Officer & Corporate Treasurer | $889,413.00 | — | 59 | $290,533.00 | 0.38% |
Heath H. Galloway | Executive Vice President, General Counsel & Corporate Secretary | $797,224.00 | — | 49 | $166,306.00 | 0.22% |
Perry A. Bernocchi | Executive VP & COO | $774,400.00 | — | 67 | $313,913.00 | 0.41% |
Colin Bain | Chief Products Officer | — | — | — | — | — |
Trudi Allcott | Director of Media Relations | — | — | — | — | — |
Will Parrish | Vice President of Strategy of Corporate Development, & Investor Relations | — | — | — | — | — |
Dirk Benson | Chief Commercial Officer | — | — | — | — | — |
Marc Rottink | Chief Operating Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$8.10M
Sells
0
$0.00
Net Sentiment
+$8.10M
Net buying
Most Active
Coliseum Capital Management, LLC
3 transactions
Analysis
Insiders reported 3 buys worth $8.10M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $8.10M. Coliseum Capital Management, LLC was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -1.4% | -2.3% (15yr)1 analysts |
| Revenue | N/A | N/A | +3.1% | -8.8% (15yr)2 analysts |
| Net Income | N/A | N/A | -1.7% | -0.9% (15yr)2 analysts |
| EBIT | N/A | N/A | -0.3% | -9.5% (15yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.1% over three years. Forward estimates point to Net Income at -0.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BioAge Labs, Inc.
NASDAQ:BIOA
$778.07M
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$535.44M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$490.18M
Cabaletta Bio, Inc.
NASDAQ:CABA
$470.41M
Canopy Growth Corporation
NASDAQ:CGC
$405.86M
Sight Sciences, Inc.
NASDAQ:SGHT
$280.21M
Editas Medicine, Inc.
NASDAQ:EDIT
$256.99M
High Tide Inc.
NASDAQ:HITI
$204.73M
CVRx, Inc.
NASDAQ:CVRX
$131.62M
Outset Medical, Inc.
NASDAQ:OM
$87.03M
Who manages ACH?
Accendra Health, Inc. (ACH) lists 9 active executives. The top listed executive is Heath H. Galloway, Executive Vice President, General Counsel & Corporate Secretary.
Are ACH insiders buying or selling?
Recent insider activity shows net buying of $14.83M.
Explore More
Continue the stock analysis
Jump to another research area for this company.